AEON Biopharma SEC filings document its ABP-450 biosimilar program, operating and financial results, governance matters, capital structure, and NYSE American listing-status disclosures. Form 8-K reports cover material events such as financial results, Regulation FD presentations, executive appointments and compensatory arrangements, and continued-listing rule notices tied to stockholders’ equity requirements.
Proxy statements record shareholder voting procedures and meeting proposals, including capital-structure approvals tied to Class A common stock, warrants, and senior secured convertible note matters. The filings also identify AEON’s Class A common stock listed on NYSE American and describe disclosure topics common to a development-stage biopharmaceutical issuer.
AEON Biopharma, Inc. reported that NYSE American sent an additional notice stating the company no longer meets an extra continued listing standard. The exchange requires stockholders’ equity of at least $4.0 million when a company has losses in three of its four most recent fiscal years.
AEON instead reported a stockholders’ deficit of approximately $55 million as of December 31, 2025, along with losses in three of its four most recent fiscal years. The company is already operating under a previously accepted plan to regain compliance by August 3, 2026.
The new notice does not immediately affect trading of AEON’s Class A common stock, which will continue to list on NYSE American with a “.BC” below‑compliance indicator and inclusion on the noncompliant issuers list. If AEON fails to regain compliance by August 3, 2026, NYSE American may begin delisting proceedings, which AEON would have the right to appeal.
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing ABP-450 as a biosimilar to Botox for all approved therapeutic indications in the U.S. under the FDA’s Section 351(k) pathway. The company holds exclusive therapeutic rights to ABP-450 across the U.S., Canada, the EU, the U.K. and certain other territories and is targeting the roughly $3.3 billion U.S. therapeutic botulinum toxin market, which is projected to grow about 8% annually and is dominated by Botox.
ABP-450 is the same 900 kDa botulinum toxin complex marketed cosmetically as Jeuveau/Nuceiva and is manufactured by Daewoong in cGMP-inspected facilities. AEON is pursuing an “analytical-first” biosimilar strategy, has held multiple FDA biosimilar program (BPD) meetings, and plans to complete most analytical comparability work in 2026 before moving to the next phase of development.
The company emphasizes potential full-label clinical substitutability with Botox and a differentiated, therapy-only BLA structure that could support distinct reimbursement economics in buy-and-bill settings. However, AEON has never been profitable and reported an accumulated deficit of $470.8 million as of December 31, 2025. Management concludes there is substantial doubt about AEON’s ability to continue as a going concern without additional financing, expecting its current cash (including $4.2 million from a January 2026 closing) to fund operations only into the third quarter of 2026.
AEON Biopharma reported a sharp swing to loss for 2025 while advancing its ABP-450 biosimilar program and repairing its balance sheet. For the year ended December 31, 2025, net loss was $39,222 thousand, compared with net income of $42,005 thousand in 2024, driven largely by volatile fair value and warrant-related items.
Total operating costs and expenses were $12,803 thousand, versus $(72,985) thousand in 2024, when a large non-cash reduction in contingent consideration had boosted results. AEON ended 2025 with cash and cash equivalents of $3,006 thousand, total liabilities of $60,587 thousand, and a stockholders’ deficit of $55,027 thousand, highlighting a highly leveraged capital structure.
Strategically, the company reported positive initial analytical biosimilarity data for ABP-450 versus BOTOX, a favorable FDA BPD Type 2a meeting outlining a clear analytical path, and a $6 million PIPE financing and Daewoong note exchange that reduced outstanding debt by more than 90%.
AEON Biopharma, Inc. chief medical officer Chad Oh reported receiving equity awards of Class A common stock as compensation. On February 17, 2026, he was granted 862,500 restricted stock units that vest in four substantially equal annual installments, starting on the first anniversary of the grant date, subject to continued service.
On March 4, 2026, 1,316,872 previously cash-settled restricted stock units granted on May 21, 2025 were modified to be settled in stock instead of cash upon vesting, while keeping the same four-year vesting schedule from the 2025 grant date. After these awards, his direct holdings increased to 2,183,436 shares of Class A common stock. These are compensation-related acquisitions, not open-market purchases or sales.
AEON Biopharma appointed John Bencich as Chief Financial Officer effective March 9, 2026, and principal financial officer effective April 1, 2026, as part of a plan to strengthen its leadership during key regulatory and financing milestones. He brings more than 25 years of biotechnology and life sciences finance experience, including prior CEO, COO and CFO roles at several public and private companies.
His employment agreement provides a $450,000 base salary, a 40% target cash bonus opportunity, severance protections, and equity inducement grants of 754,717 restricted stock units and 235,849 performance-based restricted stock units under AEON’s 2025 Employment Inducement Incentive Award Plan. AEON also entered into a new employment agreement with Chief Accounting Officer Jennifer Sy, maintaining her existing pay and bonus targets while formalizing severance and change-in-control protections. The Board amended the Inducement Plan to reserve an additional 1,000,000 shares of Class A common stock for future equity awards.
AEON Biopharma, Inc. reported that executive Wilson Alexander Blair, its CLO, CSO and Corporate Secretary, acquired Class A common stock through equity compensation awards rather than open-market purchases.
On February 17, 2026, he received an award of 862,500 restricted stock units, vesting in substantially equal installments on each of the first four anniversaries of the grant date, subject to continued service. On March 4, 2026, 1,316,872 previously cash-settled restricted stock units granted on May 21, 2025 were modified to be settled in stock instead of cash, with the original four-year vesting schedule maintained. Both transactions were reported at a price of $0.00 per share and are classified as direct ownership, bringing Blair’s total directly held Class A shares to 2,183,005 after the March 4 transaction.
AEON Biopharma, Inc. reported that its principal accounting officer, Jennifer Sy, acquired Class A common stock through equity awards. On February 17, 2026, she received an award of 575,000 restricted stock units that vest in substantially equal installments over four years, subject to continued service. On March 4, 2026, 925,925 previously granted cash-settled restricted stock units from May 21, 2025 were modified to be settled in stock instead of cash, while retaining the same four-year vesting schedule.
Bancroft Robert E. reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma, Inc. reported that President and CEO Robert E. Bancroft received a grant of 3,000,000 shares of Class A Common Stock in the form of restricted stock units on February 17, 2026. The award was granted at a price of $0.00 per share.
These restricted stock units vest in substantially equal installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to his continued service. Following this award, his directly held Class A Common Stock stake reported in this filing is 3,177,103 shares.
AEON Biopharma is registering for resale up to 51,292,953 shares of its Class A common stock pursuant to registration rights and related agreements, including an Exchange Agreement, a Private Placement and a Settlement Agreement.
The registration covers Resale Shares consisting of issued shares, shares issuable upon exercise of Pre-Funded Warrants, PIPE/Warrants, True-up Warrants, Daewoong Warrants and Settlement Warrants, and the Company will receive no proceeds from sales by the Registered Holders. Shares outstanding were 25,303,058 as of January 31, 2026. The filing discloses beneficial ownership limits of 49.9% and 9.9% for certain holders and lists per-holder maximum resale examples, including Pointilist Global Macro Series 5,923,647 and Jorey A Chernett Revocable Living Trust 3,949,098.